Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has ...

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

A panel of experts who decide the national immunization schedule will meet on Tuesday for the first time in 2025, providing ...

The government is fighting in court for a plan to cut spending on overhead research costs for grantees. Primate centers fear ...

Ab­b­Vie and San­doz have re­solved their patent dis­pute over Ab­b­Vie’s block­buster im­munol­o­gy drug Rin­voq. San­doz ...

Duality Biologics, a Chinese antibody-drug conjugates startup, to go public on Hong Kong Stock Exchange with $194M IPO amid ...

In a development landscape as extensive as obesity, we think Pfizer could be better served by looking outside,' Stifel ...

The American Medical Association is urging Optum, a unit of UnitedHealth Group, to ease up on recouping the loans it provided ...

Pfizer discontinues obesity pill danuglipron after potential drug-induced liver injury in trial patient; company has GIP ...

Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they ...

Merck licenses Cyprumed's oral drug delivery platform in $493M deal to develop oral peptide formulations, potentially for GLP-1 drugs.

Tariffs on pharmaceutical products that President Donald Trump has teased for weeks are one step closer to fruition after the Department of Commerce confirmed it's launched an investigation into the ...